Donald Metcalf and the Mysterious Molecule That Made Stem Cell Donation Possible

⏱ In 30 Seconds

✓ Donald Metcalf devoted decades to understanding how the body controls blood-cell production.
✓ His research helped establish the biology of colony-stimulating factors, including G-CSF and GM-CSF.
✓ G-CSF became an important medicine for restoring neutrophils after chemotherapy and mobilising blood-forming stem cells into the bloodstream.
✓ These discoveries helped make modern peripheral blood stem-cell donation possible and have benefited millions of patients worldwide.

My First Day at WEHI

On my first day at the Walter and Eliza Hall Institute of Medical Research, now known as WEHI, I expected to meet a new laboratory, unfamiliar colleagues and a completely different research environment.

I did not expect to meet Donald Metcalf.

It was 1 July 2011.

The first person I met was Rosie, the receptionist, who called my new supervisor, Ben, to come and collect me.

Soon afterwards, Ben introduced me to Don Metcalf as a new postdoctoral researcher from South Korea.

Don asked me:

“Whereabouts?”

He meant which part of South Korea I came from.

I was so nervous that I misunderstood the question completely. I thought he was asking where South Korea was, so I repeated it back:

“Where is South Korea?”

Both Ben and Don burst out laughing.

That was my first encounter with a scientist whose work had already transformed modern medicine.

At the time, however, he was simply a kind man who smiled, asked where I came from and shared a brief laugh with a nervous new researcher.

The Scientist Behind a Medical Revolution

Professor Donald Metcalf was one of Australia’s most influential medical researchers.

His work helped reveal how the body regulates the production of blood cells through signalling molecules known as colony-stimulating factors, or CSFs.

These discoveries eventually led to medicines used to support patients during cancer treatment and to mobilise blood-forming stem cells for transplantation.

The practical impact is enormous.

Medicines built on CSF biology have been used in millions of patients worldwide.

Yet the story began not with a drug, a clinical trial or even a clearly defined medical target.

It began with an unusual observation in a laboratory dish.

An Odd Observation in a Petri Dish

In 1965, researcher Ray Bradley was growing bone-marrow cells in a semi-solid agar culture at the University of Melbourne.

Under certain conditions, the cells did not simply remain scattered throughout the dish.

They formed distinct colonies.

Each colony appeared to arise from a single precursor cell that had received a signal to survive, divide and mature.

This observation suggested that something in the culture environment was actively instructing blood-forming cells to grow.

The mysterious activity attracted the attention of Donald Metcalf at WEHI.

Metcalf had been studying the thymus, but he recognised that the colony-forming phenomenon pointed towards a much larger biological question:

How does the body control the production of different blood-cell populations?

He redirected much of his scientific career towards answering that question.

Around the same period, researchers including Yasuo Ichikawa, Dov Pluznik and Leo Sachs at the Weizmann Institute of Science in Israel were making related observations.

Together, these discoveries helped open an entirely new field of blood-cell biology.

Naming the Hidden Signals

Through the late 1960s and 1970s, Metcalf and his colleagues established that soluble factors could stimulate blood-cell precursors to form colonies.

They called these molecules colony-stimulating factors.

The factors were detected in biological fluids, and their levels could increase during infection.

This suggested that the body possessed a feedback system capable of increasing white-blood-cell production when demand rose.

During a bacterial infection, for example, the body may need to produce large numbers of neutrophils and other immune cells in a short period.

CSFs appeared to help coordinate that response.

Researchers gradually identified several members of the family, including:

G-CSF, which strongly promotes neutrophil production
GM-CSF, which acts on granulocyte and macrophage lineages and can regulate immune-cell function
M-CSF, which supports monocyte and macrophage development
Multi-CSF, later identified as interleukin-3

These discoveries revealed that blood-cell production was not a single uniform process.

It was controlled by a network of specialised molecular signals.

A simple explanation of how colony-stimulating factors support the immune response during infection can be viewed in this video about CSF biology .

Eleven Years to Purify a Molecule

Identifying biological activity was only the beginning.

The next challenge was to isolate the molecules responsible.

CSFs existed in extremely small quantities in complex biological fluids.

Purifying enough material for biochemical study required years of careful experimentation.

GM-CSF was purified after approximately eleven years of sustained effort.

Then, in 1983, a research team led by Nicos Nicola in Metcalf’s programme isolated the factor that preferentially stimulated neutrophil-forming colonies: granulocyte colony-stimulating factor, or G-CSF.

The achievement was a triumph of persistence.

Before modern high-throughput sequencing, proteomics and recombinant expression systems, researchers often had to track biological activity through repeated rounds of fractionation and testing.

Every purification step risked losing the molecule they were trying to find.

Metcalf’s programme continued because the biological question was important, even when the path to a medicine was still uncertain.

From Molecular Discovery to a Medicine

The next major turning point came when scientists cloned the genes encoding G-CSF and other colony-stimulating factors.

Gene cloning made it possible to produce these proteins using recombinant DNA technology rather than extracting tiny quantities from natural sources.

Recombinant G-CSF could now be manufactured in sufficient amounts for clinical testing.

Its medical value soon became clear.

Many chemotherapy drugs damage rapidly dividing cells.

This includes cancer cells, but it also includes healthy blood-cell precursors in the bone marrow.

As a result, patients may develop neutropenia, a dangerous reduction in infection-fighting neutrophils.

Severe neutropenia can leave a patient vulnerable to bacterial and fungal infections and may force doctors to delay or reduce chemotherapy.

Recombinant G-CSF, including the medicine filgrastim, stimulates the bone marrow to produce neutrophils more rapidly.

This can shorten the duration of severe neutropenia and reduce some of the infectious risks associated with cancer treatment.

G-CSF became one of the most widely used supportive-care medicines in oncology.

An Unexpected Second Act

G-CSF might have remained primarily a medicine for restoring neutrophil counts after chemotherapy.

Instead, researchers discovered another remarkable effect.

G-CSF could cause haematopoietic stem and progenitor cells to leave the bone marrow and enter the circulating blood.

These stem cells normally reside within specialised bone-marrow environments where molecular signals help retain them.

G-CSF alters that environment and weakens some of the interactions that keep stem and progenitor cells anchored inside the marrow.

One important pathway involves the chemokine CXCL12 and its receptor CXCR4.

Changes in this retention system allow increased numbers of blood-forming stem cells to enter the bloodstream.

This process became known as stem-cell mobilisation.

From Bone Marrow to Peripheral Blood

At WEHI, physician-scientist George Morstyn, working with Uli Dührsen and colleagues, helped demonstrate that stem and progenitor cells mobilised into peripheral blood could be collected and used for transplantation.

This finding changed the practical organisation of stem-cell transplantation.

Traditionally, blood-forming stem cells were collected by inserting needles into the pelvic bones under anaesthesia and removing bone marrow directly.

Mobilisation created another option.

Donors could receive G-CSF for several days, causing stem cells to move into the blood, where they could be collected using an apheresis machine.

This method became known as peripheral blood stem-cell donation, or PBSC donation.

For many adult donors, it avoids an operation and general anaesthesia.

How Peripheral Blood Stem-Cell Donation Works

A typical peripheral blood stem-cell donation involves three main stages.

1. Mobilisation

For several days before collection, the donor receives injections of G-CSF, usually filgrastim.

The treatment increases the number of haematopoietic stem and progenitor cells circulating in the bloodstream.

Common temporary effects include bone pain, muscle aches, fatigue and headache.

2. Apheresis

On the day of collection, blood is drawn through a needle or intravenous line and passed through an apheresis machine.

The machine separates and collects the stem-cell-rich fraction while returning most other blood components to the donor.

The procedure usually takes several hours and may occasionally need to be repeated on a second day.

3. Recovery

After G-CSF injections stop, circulating stem-cell numbers fall back towards their usual range.

Most short-term symptoms resolve soon after the donation period.

The donor’s blood-forming system continues functioning and replenishes the donated cells.

Why Bone-Marrow Donation Still Exists

Peripheral blood collection has become a common method of obtaining donor stem cells, particularly for adult recipients.

However, it has not eliminated bone-marrow donation.

The preferred source depends on the disease being treated, the recipient’s age, the transplant protocol and the balance between risks such as graft-versus-host disease and graft failure.

For some patients, including certain children and people with particular non-malignant conditions, bone marrow may still be preferred.

The importance of G-CSF mobilisation is therefore not that it replaced every bone-marrow collection.

It created a powerful additional option and transformed how many transplants could be performed.

Why This Discovery Still Matters

Donald Metcalf’s work continues to influence medicine in several distinct ways.

G-CSF supports patients whose neutrophil counts fall after chemotherapy.

It is used to mobilise stem cells for autologous and donor transplantation.

CSF biology helped establish the idea that blood-cell production is actively regulated by specific molecular signals.

That concept shaped modern haematology, immunology and cytokine biology.

The story also demonstrates why basic research matters.

Metcalf did not begin by trying to invent a stem-cell mobilisation drug.

He was trying to understand why blood-forming cells produced colonies in a laboratory culture and what invisible signals controlled their behaviour.

Decades later, that question led to medicines used during cancer treatment and to a less invasive method of collecting stem cells from many donors.

A curious observation in a petri dish became a medical technology used around the world.

A Personal Memory

Looking back, I realise how fortunate I was.

On my first day at WEHI, I met a scientist whose discoveries had already transformed medicine for millions of people.

I came to admire Don not only for the scale of his scientific achievement, but also for the persistence behind it.

He spent decades following a difficult biological question before its full clinical value became clear.

His work showed what can happen when a scientist remains committed to understanding something fundamental, even when the eventual application cannot yet be seen.

I also remember the person.

The man who smiled, asked a nervous new postdoctoral researcher where he came from and laughed kindly when the question was misunderstood.

Donald Metcalf died in 2014.

I still miss him.

His scientific legacy lives in laboratories, cancer wards, transplant centres and in the millions of people who have benefited from colony-stimulating factors.

For me, it also survives in a brief conversation from my first day at WEHI.

Sometimes the greatest scientific legacies are measured in medicines, patients and transformed lives.

Sometimes they also remain in a small human moment that is never forgotten.

Continue Reading

This article is intended for general educational purposes and is not medical advice. Anyone considering stem-cell donation or receiving G-CSF should discuss the expected benefits, risks and procedures with their healthcare or donor team.

thebiostories

Donald Metcalf: The Scientist Who Discovered G-CSF